Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to $1.4 million.

  • Bio-Techne's Change in Accured Expenses fell 9058.34% to $1.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$9.2 million, marking a year-over-year decrease of 13783.43%. This contributed to the annual value of $15.4 million for FY2025, which is 4020.72% down from last year.
  • Latest data reveals that Bio-Techne reported Change in Accured Expenses of $1.4 million as of Q4 2025, which was down 9058.34% from -$22.1 million recorded in Q3 2025.
  • Bio-Techne's 5-year Change in Accured Expenses high stood at $21.6 million for Q1 2022, and its period low was -$28.4 million during Q3 2022.
  • In the last 5 years, Bio-Techne's Change in Accured Expenses had a median value of $2.6 million in 2024 and averaged $1.0 million.
  • As far as peak fluctuations go, Bio-Techne's Change in Accured Expenses soared by 204967.95% in 2021, and later plummeted by 30486.09% in 2024.
  • Bio-Techne's Change in Accured Expenses (Quarter) stood at $8.5 million in 2021, then crashed by 157.54% to -$4.9 million in 2022, then soared by 264.67% to $8.1 million in 2023, then surged by 83.15% to $14.8 million in 2024, then crashed by 90.58% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q4 2025, -$22.1 million for Q3 2025, and $3.4 million during Q2 2025.